UCB sign
Pharma

UCB shares results for Bimzelx's PsA triumph over Skyrizi

In a head-to-head psoriatic arthritis trial, UCB's Bimzelx achieved reduced disease activity in 49% of patients vs. 38% of those on AbbVie's Skyrizi.
Kevin Dunleavy May 19, 2026 11:27am
Xofluza

Roche signs generic Xofluza licensing deal with MPP

May 19, 2026 11:15am
The Case for Direct-to-Patient Is Clear The Challenge Now is Successful Execution

DTP is Decided: Now Comes the Hard Part

Brought to you by Gifthealth
Drug Prices

TrumpRx site updated to include hundreds of generic medications

May 19, 2026 11:04am
SQ81054png

Doceree launches Daily Command, an AI platform for brand teams co-built by pharma leaders

Brought to you by Doceree
President Trump speaks in the Oval Office

Trump bought stock in drugmaker as admin boosted its obesity drugs

May 19, 2026 8:47am
More News

Jury awards $885M in Takeda pay-for-delay antitrust case

May 19, 2026 8:39am

Novartis in plant contract dispute with Chinese CDMO Porton

May 18, 2026 4:27pm

Supreme Court declines to hear IRA challenges from 6 pharmas

May 18, 2026 3:06pm

Regulatory tracker: Japan hands out nods to Roche, BI, GSK

May 18, 2026 2:30pm